BZ-371A(BZ-371A) - 在研适应症：女性性功能障碍，心理性性功能障碍，勃起功能障碍_专利_临床

概要

基本信息

药物类型

合成多肽

别名

靶点-

作用机制

一氧化氮刺激剂

治疗领域

肿瘤泌尿生殖系统疾病其他疾病

在研适应症

女性性功能障碍心理性性功能障碍勃起功能障碍+ [1]

非在研适应症

糖尿病性视网膜病变干性年龄相关性黄斑病变青光眼+ [1]

原研机构

Biozeus Biopharmaceutical SA

在研机构

Biozeus Biopharmaceutical SA

非在研机构-

最高研发阶段临床2期

首次获批日期-

最高研发阶段(中国)-

特殊审评孤儿药 (美国)

登录后查看时间轴

序列信息

Sequence Code 13382751

来源: *****

关联

4

项与 BZ-371A 相关的临床试验

NCT06651541 / Not yet recruiting临床2期

Phase 2 Parallel Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women with Sexual Arousal Disorder

Evaluation of the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder

开始日期2025-07-01

申办/合作机构

Biozeus Biopharmaceutical SA

NCT06116045 / Recruiting临床2期

Phase 2 Clinical Study to Evaluate the Efficacy in Increasing Sexual Arousal, Safety and Tolerability of BZ371A in Gel Form Applied to Women with Sexual Arousal Disorder

To determine the efficacy in increasing sexual arousal, safety and tolerability of BZ371A in gel form applied to women with sexual arousal disorder.

开始日期2024-10-01

申办/合作机构

Biozeus Biopharmaceutical SA

NCT05558007 / Recruiting临床2期

Phase 2 Clinical Trial to Evaluate Safety and Efficacy of BZ371A in a Gel Applied in Patients That Performed Radical Prostatectomy

To determine efficacy, safety and tolerabiltiy of topically applied BZ371A in patients that experienced RP, in combination with daily tadalafil compared to placebo.

开始日期2023-11-22

申办/合作机构

Biozeus Biopharmaceutical SA

100 项与 BZ-371A 相关的临床结果

登录后查看更多信息

100 项与 BZ-371A 相关的转化医学

登录后查看更多信息

100 项与 BZ-371A 相关的专利（医药）

登录后查看更多信息

11

项与 BZ-371A 相关的文献（医药）

2023-09-07·Toxins

PnPP-15, a Synthetic Peptide Derived from a Toxin from Phoneutria nigriventer Spider Venom, Alleviates Diabetic Neuropathic Pain and Acts Synergistically with Pregabalin in Mice.

Article

作者: de Assis Ferreira, Luana Caroline ; Almeida-Leite, Camila Megale ; de Lima, Maria Elena ; Mariano, Xavier Maia ; de Castro Junior, Célio José

Diabetic neuropathic pain is one of the complications that affect a wide variety of the diabetic population and is often difficult to treat. Only a small number of patients experience pain relief, which usually comes with onerous side effects and low levels of satisfaction. The search for new analgesic drugs is necessary, given the limitations that current drugs present. Combining drugs to treat neuropathic pain has been attracting interest to improve their efficacy compared to single-drug monotherapies while also reducing dose sizes to minimize side effects. The aim of our study was to verify the antinociceptive effect of a synthetic peptide, PnPP-15, alone and combined with pregabalin, in male Swiss diabetic mice using the von Frey method. PnPP-15 is a synthetic peptide derived from PnPP19, a peptide representing a discontinuous epitope of the primary structure of the toxin PnTx2-6 from the venom of the spider Phoneutria nigriventer. The antinociceptive activity of both compounds was dose-dependent and showed synergism, which was verified by isobolographic analysis. Treatment with PnPP-15 did not cause spontaneous or forced motor changes and did not cause any damage or signs of toxicity in the analyzed organs (pancreas, lung, heart, kidney, brain, or liver). In conclusion, PnPP-15 is a great candidate for an analgesic drug against neuropathic pain caused by diabetes and exerts a synergistic effect when combined with pregabalin, allowing for even more efficient treatment.

2021-09-01·Nitric Oxide2区 · 生物学

The synthetic peptide PnPP-19 potentiates erectile function via nNOS and iNOS

2区 · 生物学

Article

作者: Silva, Carolina Nunes da ; Lemos, Vírginia S ; de Lima, Maria Elena ; Almeida, Flávia De Marco ; Gomez, Ricardo Santiago ; Gomes, Dawidson Assis ; Pedrosa, Kenia Nunes ; Diniz, Thiago F ; Maia, Luísa Michette S ; Silva, Grazielle Caroline da ; Cunha, Pricila da Silva

PnPP-19 peptide has a primary sequence design based on molecular modeling studies of PnTx2-6 toxin. It comprises the amino acid residues that are potentially significant for the pharmacological action of PnTx2-6. Ex vivo and in vivo experiments in normotensive, hypertensive, or diabetic murine models have shown a significant improvement in penile erection after administration of PnPP-19. Given the potential use of PnPP-19 in pharmaceutical formulations to treat erectile dysfunction and the lack of information concerning its mode of action, the present work investigates its activities on the nitrergic system. PnPP-19 induced a significant increase in nitric oxide (NO) and cGMP levels in corpus cavernosum (cc). These effects were inhibited by l-NAME, a non-selective inhibitor of nitric oxide synthase (NOS); were partially inhibited by 7- Nitroindazole, a selective inhibitor of neuronal NOS (nNOS); and were abolished by L-NIL, a selective inhibitor of inducible NOS (iNOS). This potentiating effect was not affected by atropine. PnPP-19 also led to changes in mRNA levels, protein expression and phosphorylation at specific sites of NOS, in cc. Assays using cavernous tissue from knockout mice to endothelial NOS (eNOS), nNOS or iNOS showed that PnPP-19 potentiates relaxation only in eNOS-knockout mice, which suggests an essential role for nNOS. Surprisingly, iNOS enhanced the potentiation of erectile function evoked by PnPP-19. Our results demonstrate that this new synthetic peptide potentiates erectile function via nitric oxide activation and reinforce its role as a new pharmacological tool for the treatment of erectile dysfunction.

2020-10-01·Toxicon3区 · 医学

Pain modulatory properties of Phoneutria nigriventer crude venom and derived peptides: A double-edged sword

3区 · 医学

Review

作者: Casais-E-Silva, Luciana Lyra ; Villarreal, Cristiane Flora ; Lauria, Pedro Santana Sales

Phoneutria nigriventer venom (PNV) is a complex mixture of toxins exerting multiple pharmacological effects that ultimately result in severe local pain at the site of the bite. It has been proposed that the PNV-induced pain is mediated by both peripheral and central mechanisms. The nociception triggered by PNV is peripherally mediated by the activation of B₂, 5-HT₄, NMDA, AMPA, NK₁, and NK₂ receptors, as well as TTXS-Na⁺, ASIC, and TRPV1 channels. The activation of tachykinin, glutamate and CGRP receptors along with the production of inflammatory mediators are, at least partially, responsible for the central component of pain. Despite its well established pro-nociceptive properties, PNV contains some toxins with antinociceptive activity, which have been studied in the last few years. The toxins ω-CNTX-Pn4a, ω-CNTX-Pn2a, ω-CNTX-Pn3a, κ-CNTX-Pn1a, U₇-CNTX-Pn1a, δ-CNTX-Pn1a, and Γ-CNTX-Pn1a from PNV, as well as the semi-synthetic peptide PnPP-19 have been tested in different experimental models of pain showing consistent antinociceptive properties. This review aims to discuss the pro- and antinociceptive actions of PNV and its toxins, highlighting possible mechanisms involved in these apparently dualistic properties.

100 项与 BZ-371A 相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
女性性功能障碍	临床2期	巴西	Biozeus Biopharmaceutical SA	2025-07-01
心理性性功能障碍	临床2期	巴西	Biozeus Biopharmaceutical SA	2024-10-01
勃起功能障碍	临床2期	巴西	Biozeus Biopharmaceutical SA	2023-11-22
前列腺癌	临床2期	巴西	Biozeus Biopharmaceutical SA	2023-11-22